ClinVar Miner

Submissions for variant NM_004004.6(GJB2):c.94C>T (p.Arg32Cys) (rs371024165)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 9
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
EGL Genetic Diagnostics, Eurofins Clinical Diagnostics RCV000724651 SCV000331831 pathogenic not provided 2018-02-09 criteria provided, single submitter clinical testing
Laboratory for Molecular Medicine, Partners HealthCare Personalized Medicine RCV000614720 SCV000710857 pathogenic Rare genetic deafness 2017-10-26 criteria provided, single submitter clinical testing The p.Arg32Cys variant in GJB2 has been reported in at least 13 individuals with hearing loss, including 3 homozygotes and 8 compound heterozygotes, and segrega ted with hearing loss in two additional family members in two families (Prasad 2 000, Cryns 2004, Primignani 2009, Dai 2009, Shan 2010, Dodson 2011, Bazazzadegan 2012, Xia 2016, Moctar 2016, LMM data). This variant has also been reported in ClinVar (Variation ID# 188758) as likely pathogenic. It has been identified in 10/24020 African chromosomes by the Genome Aggregation Database (gnomAD, http:// gnomad.broadinstitute.org; dbSNP rs371024165); however, its frequency is low eno ugh to be consistent with the carrier frequency for recessive hearing loss. In s ummary, the p.Arg32Cys variant meets criteria to be classified as pathogenic for autosomal recessive hearing loss based on the previously reported homozygous an d compound heterozygous affected individuals and statistically significant incre ase of allele frequency in affected individuals over the general population. ACM G/AMP Criteria applied: PM3_S; PS4 (Richards 2015).
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000169075 SCV000917436 pathogenic Deafness, autosomal recessive 1A 2017-09-01 criteria provided, single submitter clinical testing Variant summary: The GJB2 c.94C>T (p.Arg32Cys) variant causes a missense change involving the alteration of a conserved nucleotide located in the Connexin, N-terminal domain (IPR013092) (InterPro). 5/5 in silico tools predict damaging outcome for this variant. The variant was found in the control population dataset of ExAC and publications in 5/122742 control chromosomes at a frequency of 0.0000407, which does not exceed the estimated maximal expected allele frequency of a pathogenic GJB2 variant (0.025). This variant was reported in several patients with NSHL in homozygous state and compound heterozygous state with other pathogenic variants, including evidence of cosegregation with disease (Prasad_2000, Pandya_2003, Toth_2004, Snoeckx_2005, Dai_2009, Shan_2010, Dodson_2011, Bazazzadegan_2012, Rayess_2015). Multiple clinical diagnostic laboratories/reputable databases classified this variant as likely pathogenic. Another missense change at the same residue p.Arg32His has also been classified as pathogenic by multiple submitters in ClinVar. Taken together, this variant is classified as pathogenic.
Athena Diagnostics Inc RCV000724651 SCV001143676 pathogenic not provided 2020-10-21 criteria provided, single submitter clinical testing The frequency of this variant in the general population is consistent with pathogenicity (http://gnomad.broadinstitute.org). This variant appears to segregate with disease in at least one family, however, the available information does not rule out segregation due to chance. In multiple individuals, this variant has been seen with a single recessive pathogenic variant in the same gene, suggesting this variant may also be pathogenic. Computational tools predict that this variant is damaging.
ARUP Laboratories, Molecular Genetics and Genomics,ARUP Laboratories RCV001001448 SCV001158689 pathogenic not specified 2018-09-28 criteria provided, single submitter clinical testing The GJB2 (Connexin 26) c.94C>T; p.Arg32Cys variant (rs371024165) has been previously identified in patients with a suspicion of GJB2-realted deafness, either as a homozygote (Moctar 2016), or as part of a trans-heterozygous (bi-allelic) combination with another pathogenic variant (Prasad 2000, Xia 2016, Moctar 2016). It has also been identified as a rare variant in several large-scale sequencing studies of affected populations (selected references: Snoeckx 2005, Dodson 2011, de la Luz Arenas-Sordo 2012, Bazazzadegan 2012). Consistent with a recessive carrier frequency, this variant is found in the general population with an allele frequency in African populations of 0.04% (10/24,020 alleles) in the Genome Aggregation Database. The arginine residue at this position is highly conserved across multiple species (Alamut Software v 2.11), and computational programs (SIFT, PolyPhen2) predict this variant to be damaging to protein function. Additionally, as listed in the HGMD database (Stenson 2017) other amino acid substitutions at this codon have been implicated in hearing loss (Gly, His, Leu, Ser). Taken together, we consider the c.94C>T; p.Arg32Cys variant to be pathogenic.
Invitae RCV000724651 SCV001391719 pathogenic not provided 2020-08-20 criteria provided, single submitter clinical testing This sequence change replaces arginine with cysteine at codon 32 of the GJB2 protein (p.Arg32Cys). The arginine residue is highly conserved and there is a large physicochemical difference between arginine and cysteine. This variant is present in population databases (rs371024165, ExAC 0.04%). This variant has been observed as homozygous or in combination with another GJB2 variant in individual(s) with congenital autosomal recessive non-syndromic hearing loss (PMID: 11102979, 27045574, 21465647, 19371219, 26346709). In at least one individual the data is consistent with the variant being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 188758). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. This variant disrupts the p.Arg32 amino acid residue in GJB2. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 22925408, 20154630, 19157576). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.
GeneDx RCV000724651 SCV001827024 pathogenic not provided 2021-04-05 criteria provided, single submitter clinical testing In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 30275481, 19371219, 11102979, 15365987, 19390476, 26346709, 15146474, 22695344, 31163360, 21465647, 12885339, 15967879, 17666888, 19157576, 19235794, 20083784, 22925408, 26540915, 25270357, 16380907, 12865758, 27067584, 20381175, 14985372, 25388846, 25087612, 27153395, 27045574, 19366456)
Counsyl RCV000169075 SCV000220243 pathogenic Deafness, autosomal recessive 1A 2016-09-09 no assertion criteria provided clinical testing
Natera, Inc. RCV000169075 SCV001453359 pathogenic Deafness, autosomal recessive 1A 2020-09-16 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.